Dual antagonist of PGD2/DPr2 and Thromboxane A2/TPr receptors and use for treatment of maladaptive immune response or thrombotic diathesis
The present invention relates to a pharmaceutical composition for treatment of a disease or condition characterized by or associated with stimulation of both DPr2 and TPr signaling, said composition comprising an effective amount of a dual receptor antagonist of DPr2 for prostaglandin D2 and TPr for thromboxane A2 and a pharmaceutically acceptable carrier..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 21. Feb. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
GUPTA AJAY [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-02-21, Last update posted on www.tib.eu: 2024-03-27, Last updated: 2024-03-29 |
|---|
| Patentnummer: |
US11583517 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA002829320 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA002829320 | ||
| 003 | DE-627 | ||
| 005 | 20240329160934.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240329s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA002829320 | ||
| 035 | |a (EPA)US11583517 | ||
| 035 | |a (EPA)77928261 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a GUPTA AJAY |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dual antagonist of PGD2/DPr2 and Thromboxane A2/TPr receptors and use for treatment of maladaptive immune response or thrombotic diathesis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-02-21, Last update posted on www.tib.eu: 2024-03-27, Last updated: 2024-03-29 | ||
| 520 | |a The present invention relates to a pharmaceutical composition for treatment of a disease or condition characterized by or associated with stimulation of both DPr2 and TPr signaling, said composition comprising an effective amount of a dual receptor antagonist of DPr2 for prostaglandin D2 and TPr for thromboxane A2 and a pharmaceutically acceptable carrier. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a CHIANG KATE CHANDER |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 21. Feb. |
| 773 | 1 | 8 | |g year:2023 |g day:21 |g month:02 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/77928261/publication/US11583517A1?q=US11583517 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 21 |c 02 | ||